Clinical Trial

Effects of BLa80 and LRa05 on the Gut Microbiota Metabolite Profile of Healthy Individuals

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
Gut microbiota play a key role in polyphenol metabolism, participating in the breakdown of dietary components and producing various small molecule metabolites that affect human health. However, little is currently known about how gut microbes metabolize dietary compounds and produce bioactive metabolites. This study aims to use metabolomics to precisely identify food-derived metabolites in the blood to investigate whether probiotics (BLa80, LRa05) can enhance the breakdown of dietary components and improve their absorption and utilization in the human body.
Trial Details
NCT Number NCT07287306
Lead Sponsor Wecare Probiotics Co., Ltd.
Conditions Healthy Individuals
Enrollment 375 participants
Start Date 2025-12-10
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-17